Humacyte (HUMA) has received a minimum purchase commitment of $1.475M of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals within the Kingdom of Saudi Arabia. The planned clinical evaluation program is to be conducted in parallel with ongoing negotiations with a KSA-based entity for establishment of a joint venture and license to commercialize Symvess within the country. Humacyte will provide personnel to train medical professionals in the use of Symvess as part of the program and has agreed to not engage in negotiation of commercialization rights within the KSA with any other party through July 2, 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte submits MAA for Symvess in Israel for vascular trauma repair
- Largest borrow rate increases among liquid names
- Humacyte announces presentation of Symvess long-term safety, efficacy results
- Humacyte reports new DoD funding for procurement of bioengineered blood vessels
- Humacyte price target lowered to $10 from $11 at Benchmark